Recent focus on this breast cancer subtype relates to resistance to endocrine and anti-HER2 directed therapy, phenotypic similarity to breast cancers in BRCA1/2 mutation carriers and the development of polyADP-ribose polymerase (PARP) inhibitors which have demonstrated promising activity in this disease. Here, ERBB2 is linked to breast cancer.